The estimated Net Worth of David B. Weiner is at least $1.14 Миллион dollars as of 15 May 2024. David Weiner owns over 2,166 units of Inovio Pharmaceuticals Inc stock worth over $540,434 and over the last 9 years he sold INO stock worth over $408,947. In addition, he makes $193,151 as Director at Inovio Pharmaceuticals Inc.
David has made over 22 trades of the Inovio Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 2,166 units of INO stock worth $14,187 on 15 May 2024.
The largest trade he's ever made was selling 26,583 units of Inovio Pharmaceuticals Inc stock on 21 April 2021 worth over $227,816. On average, David trades about 8,070 units every 71 days since 2016. As of 15 May 2024 he still owns at least 82,509 units of Inovio Pharmaceuticals Inc stock.
You can see the complete history of David Weiner stock trades at the bottom of the page.
Dr. David B. Weiner Ph.D. serves as Director of the Company. Dr. Weiner qualifies to serve on our Board as he is a recognized leader in immunology as well as in gene vaccines and therapy. Since 2016, Dr. Weiner has served as Executive Vice President and Director of the Vaccine Center at The Wistar Institute, the nation’s first independent biomedical research institute, which is also an NCI-designated Cancer Center and an international leader in cancer, immunology and infectious disease research. Dr. Weiner is also the W. W. Smith Charitable Trust Professor of Cancer Research at The Wistar Institute. Previously, Dr. Weiner was Professor of Pathology & Laboratory Medicine at the University of Pennsylvania and Chair of the Gene Therapy and Vaccine Program at the University’s Perelman School of Medicine. He has more than 350 peer-reviewed publications in scientific journals, including mainstream scientific journals such as Scientific American, and has been designated by the Institute for Scientific Information as one of the top-cited scientists in the world. An inventor and holder of more than 100 issued and pending U.S. patents, Dr. Weiner has received numerous honors including election as a fellow to the American Association for the Advancement of Science in 2011 and the International Society for Vaccines in 2012. He was the recipient of the NIH Director’s Transformative Research Award and received the Vaccine Industry Excellence Award for Best Academic Research Team in 2015 at the World Vaccine Congress. Dr. Weiner was honored with the prestigious Hilleman Lectureship in 2015 at the Children’s Hospital of Philadelphia Grand Rounds session and received a Stone Family Award from Abramson Cancer Center for his groundbreaking work on DNA vaccines for cancer immune therapy. Dr. Weiner holds a Ph.D. in developmental biology from the University of Cincinnati College of Medicine, an M.S. in biology from the University of Cincinnati and a B.S. in biology from SUNY at Stony Brook in Stony Brook, New York.
As the Director of Inovio Pharmaceuticals Inc, the total compensation of David Weiner at Inovio Pharmaceuticals Inc is $193,151. There are 8 executives at Inovio Pharmaceuticals Inc getting paid more, with Jong Kim having the highest compensation of $2,588,530.
David Weiner is 64, he's been the Director of Inovio Pharmaceuticals Inc since 2016. There are 2 older and 12 younger executives at Inovio Pharmaceuticals Inc. The oldest executive at Inovio Pharmaceuticals Inc is Simon Benito, 75, who is the Independent Chairman of the Board.
David's mailing address filed with the SEC is 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING, PA, 19462.
Over the last 19 years, insiders at Inovio Pharmaceuticals Inc have traded over $23,656,819 worth of Inovio Pharmaceuticals Inc stock and bought 1,958,377 units worth $5,174,071 . The most active insiders traders include Austin W & Greenhouse David..., Jong Joseph Kim и Felix Theeuwes. On average, Inovio Pharmaceuticals Inc executives and independent directors trade stock every 22 days with the average trade being worth of $745,390. The most recent stock trade was executed by Michael John Sumner on 30 June 2024, trading 2,917 units of INO stock currently worth $19,106.
inovio is revolutionizing the fight against cancer and infectious diseases. our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, and have shown clinically significant efficacy with a favorable safety profile. with an expanding portfolio of immune therapies, the company is advancing a growing preclinical and clinical stage product pipeline. partners and collaborators include roche, medimmune, university of pennsylvania, darpa, drexel university, nih, hiv vaccines trial network, national cancer institute, u.s. military hiv research program, and university of manitoba. for more information, visit www.inovio.com.
Inovio Pharmaceuticals Inc executives and other stock owners filed with the SEC include: